Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.23.1
Condensed Consolidated Balance Sheets - USD ($)
Mar. 31, 2023
Jun. 30, 2022
Current assets:    
Cash and cash equivalents $ 6,562,000 $ 22,676,000
Investments in debt securities   10,845,000
Accounts receivable - trade 70,000 1,000,000
Subscription receivable 260,000  
Settlement receivable - current portion   5,100,000
Convertible promissory note receivable and accrued interest 912,000  
Prepaid expenses and other current assets 921,000 1,549,000
Current assets held for sale 18,368,000 3,900,000
Total Current Assets 27,093,000 45,070,000
Restricted cash 3,253,000 5,996,000
Convertible promissory note receivable and accrued interest 775,000 1,631,000
Finance lease right-of-use assets, net of accumulated amortization 678,000  
Operating lease right-of-use asset 2,786,000 3,068,000
Fixed assets, net of accumulated depreciation 4,358,000 1,373,000
Intangible assets, net of accumulated amortization 5,393,000 4,851,000
Security deposits 50,000 29,000
Prepaid expenses - noncurrent   74,000
Noncurrent assets held for sale   37,314,000
Total Assets 44,386,000 99,406,000
Current liabilities:    
Accounts payable 2,013,000 4,264,000
Accrued expenses 3,821,000 3,764,000
Finance lease obligations - current portion 265,000  
Operating lease obligation - current portion 377,000 91,000
Equipment financing payable - current portion 156,000  
Term note payable - net of deferred financing costs 13,700,000 22,161,000
Contract liabilities 0 100,000
Current liabilities related to assets held for sale 1,944,000 56,000
Total Current Liabilities 22,276,000 30,436,000
Finance lease obligations - net of current portion 422,000  
Operating lease obligation - net of current portion 3,225,000 3,514,000
Equipment financing payable - net of current portion 283,000  
Accrued expenses - noncurrent 791,000  
Noncurrent liabilities related to assets held for sale   1,971,000
Total Liabilities 26,997,000 35,921,000
iBio, Inc. Stockholders' Equity:    
Series 2022 Convertible Preferred Stock - $0.001 par value; 1,000,000 shares authorized; 0 and 1,000 shares issued and outstanding as of March 31, 2023 and June 30, 2022, respectively
Common stock - $0.001 par value; 275,000,000 shares authorized at March 31, 2023 and June 30, 2022; 15,818,149 and 8,727,158 shares issued and outstanding as of March 31, 2023 and June 30, 2022, respectively 16,000 9,000
Additional paid-in capital 300,280,000 287,619,000
Accumulated other comprehensive loss   (213,000)
Accumulated deficit (282,907,000) (223,930,000)
Total Stockholders' Equity 17,389,000 63,485,000
Total Liabilities and Stockholders' Equity $ 44,386,000 $ 99,406,000